|
 |
| home > epc > summer 2003 > advances in lc/ms/ms for drug metabolite characterisation e-data |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
In the last few years the applications of mass spectrometry have expanded dramatically, with the fields of proteomics and biotechnology showing the fastest growth. Mass spectrometers have continually undergone technological developments to keep pace, usually improving sensitivity and throughput. However, most instruments still have an Achilles' heel which requires two or more different methods to be combined in order to obtain all of the data that is needed.
Take, for example, quadrupole and ion trap analysers. On triple quadrupole instruments, the sensitivity in product ion scan mode is often not sufficient to obtain good spectra quality. QqTOF technology can overcome this lack of sensitivity with additional accurate mass information, but true precursor and neutral loss scan experiments and reliable quantitative analysis are not possible. The same applies to ion trap technology, although ion trap MS does allow sensitive multiple MS (MSn) experiments to clarify the fragmentation process, which simplifies the spectral interpretation.
These limitations have posed challenges for the pharmaceutical industry, where bioanalytical support for drug metabolism and pharmacokinetics requires powerful, sensitive instruments. The investigation of any potential new drug involves the characterisation of its metabolites in an in vitro system and LC/MS has emerged as a sensitive, rapid and highly automated technique for this.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Aegate Proves Authenticating Drugs at the Point of Dispensing Protects Consumers
More info >> |
|
 |
